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Abstract 
  Bone is a dynamic tissue being continuously remodeled by the coordinated actions of 
the bone resorbing osteoclasts and bone forming osteoblast lineage cells. This bone 
turnover is essential to maintain bone strength and mineral homeostasis, and an 
imbalance between bone formation and resorption—an increased activity of osteoclasts 
compared to osteoblasts—leads to osteoporosis, which represents a net loss of bone 
mass and ultimately an increased fracture risk. Although multiple antiresorptive agents 
which inhibit the activity of osteoclasts and reduce bone resorption have been developed, 
there is still an unmet medical need for creating new agents for the treatment of 
osteoporosis that provide enough reduction in the risk of fractures, and also provide 
long-term safety with less concerns about adverse effects of the treatment. I started my 
current studies in order to identify novel genes involved in the function of osteoclasts 
and to validate them as new molecular targets for anti-osteoporosis drugs. As a result of 
in silico screening using a human gene expression database, I found sialic acid-binding 
immunoglobulin-like lectin 15 (Siglec-15) to be one of the genes markedly 
overexpressed in giant cell tumor of bone which is a locally aggressive intraosseous 
neoplasm and characterized by clinical findings of osteolytic bone destruction. The 
mRNA expression level of Siglec-15 increased in association with osteoclast 
differentiation in cultures of mouse primary unfractionated bone marrow cells (UBMC), 
RAW264.7 cells of the mouse macrophage cell line, and human osteoclast precursors 
(OCP), indicating this gene’s relationship with osteoclast differentiation. Treatment with 
polyclonal antibody to mouse Siglec-15 markedly inhibited osteoclast differentiation in 
primary mouse bone marrow-derived monocyte/macrophage (BMM) cells stimulated 
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with the receptor activator of nuclear factor κB ligand (RANKL) or tumor necrosis 
factor-α (TNF-α). The antibody also inhibited osteoclast differentiation in cultures of 
mouse UBMC and RAW264.7 cells stimulated with active vitamin D3 and RANKL, 
respectively. Similarly to mouse cells, treatment with polyclonal antibody to human 
Siglec-15 inhibited RANKL-induced tartrate-resistant acid phosphatase 
(TRAP)-positive multinuclear cell formation in human OCP cultures. These results 
suggest an important role of Siglec-15 in mouse and human osteoclast differentiation 
and the potential use of antibody targeting Siglec-15 for treating bone disorders related 
to increased osteoclast activity. To discern the physiological role of Siglec-15 in skeletal 
development and osteoclast formation and/or function in vivo, I generated 
Siglec-15-deficient (Siglec15
−/−
) mice and analyzed their phenotype. The Siglec15
−/−
 
mice developed without physical abnormalities other than increased trabecular bone 
mass in lumbar vertebrae and metaphyseal regions of the femur and tibia, causing mild 
osteopetrosis. Histological analyses demonstrated that the number of osteoclasts present 
on the femoral trabecular bone of the mutant mice was comparable to that of the 
wild-type mice. However, urinary deoxypyridinoline, a systemic bone resorption marker, 
decreased in the Siglec15
−/−
 mice, suggesting that the impaired osteoclast function was 
responsible for increased bone mass in the mutant mice. In addition, the ability of BMM 
from the Siglec15
−/−
 mice to differentiate into osteoclasts was impaired, as determined 
in vitro by cellular TRAP activity in response to RANKL or TNF-α. These results reveal 
the importance of Siglec-15 in the regulation of osteoclast formation and/or function in 
vivo, providing new insights into the biology of osteoclasts. The findings in the current 
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studies will provide new opportunities to develop therapeutics targeting Siglec-15 for 
the treatment of osteoporosis.  
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Abbreviations 
BMM bone marrow-derived monocyte/macrophage 
CLEC4A C-type lectin domain family 4, member A 
DAP12 DNAX-activating protein of 12 kDa 
DPD deoxypyridinoline 
FcRγ Fc receptor γ subunit 
GCT giant cell tumor of bone 
IgLRs immunoglobulin-like receptors 
IL-1 interleukin-1 
ITAM immunoreceptor tyrosine-based activation motif 
M-CSF macrophage colony-stimulating factor 
MEGF10 multiple EGF-like-domains 10 
NFATc1 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1 
OCP osteoclast precursors 
PLCγ phospholipase Cγ 
pQCT peripheral quantitative computed tomography 
RANK receptor activator of nuclear factor κB 
RANKL receptor activator of nuclear factor κB ligand 
Siglec-15 sialic acid-binding immunoglobulin-like lectin 15 
TNF-α tumor necrosis factor-α 
TRAF6 tumor necrosis factor receptor-associated factor 6 
TRAP tartrate-resistant acid phosphatase 
TREM-2 triggering receptor expressed on myeloid cells 2 
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UBMC unfractionated bone marrow cells 
vBMC volumetric bone mineral content  
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General Introduction 
  Bone is a dynamic tissue being continuously remodeled by the coordinated actions of 
the bone resorbing osteoclasts and bone forming osteoblast lineage cells [1]. This bone 
turnover—resorbing old bone and forming new bone—is essential to maintain bone 
strength and mineral homeostasis during adulthood. In physiological conditions, the 
balance between bone formation and resorption is appropriately regulated, and these 
opposing processes interact to form a functional coupling [2]. 
  Osteoporosis is the most common bone disease in humans representing a major 
public health problem, and is characterized by low bone mass, compromised bone 
strength and an increase in the risk of fracture. Osteoporosis is a systemic skeletal 
disease that results from an imbalance between bone formation and resorption; an 
increased activity of osteoclasts compared to osteoblasts leads to a net loss of bone mass 
and ultimately an increased fracture risk. Drugs for osteoporosis treatment are classified 
as either antiresorptive or anabolic. Antiresorptive agents inhibit the activity of 
osteoclasts and reduce bone resorption, while anabolic agents activate osteoblasts and 
stimulate bone formation. Currently in the US, multiple antiresorptive agents are 
available for the prevention and/or treatment of postmenopausal osteoporosis, which 
include bisphosphonates, calcitonin, estrogen, selective estrogen receptor modulators, 
and the receptor activator of nuclear factor κB ligand (RANKL) inhibitor [3, 4]. 
Bisphosphonates [5] are the most widely used drugs, owing to their potent effects in 
inhibiting bone resorption. Recently, concerns of rare but serious complications, such as 
osteonecrosis of the jaw [6, 7] and atypical femoral fractures [8, 9], have been raised 
with long-term bisphosphonate use. Although the actual risk of these complications 
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associated with the use of bisphosphonates remains uncertain, and further studies are 
needed to clarify their pathogenesis and true incidence rate, it is considered that the 
dramatic decrease in bone turnover with these potent antiresorptive treatments underlies 
the cause of such complications. Thus, there is still an unmet medical need for creating 
new agents for osteoporosis treatment that provide enough reduction in the risk of 
fractures and also provide long-term safety with less concern of adverse effects. 
  Osteoclasts are multinucleated cells positive for tartrate-resistant acid phosphatase 
generated from mononuclear monocyte/macrophage lineage hematopoietic precursors 
[10], and resorb bone by secreting protons and proteases such as cathepsin K into the 
resorption lacunae. In functional coupling, osteoblasts regulate osteoclast formation 
both by secreting factors such as macrophage colony-stimulating factor, interleukin-1 
(IL-1), and IL-6 [11], and by direct interaction with osteoclast precursors [12, 13]. 
Among such osteoblast-derived factors, RANKL is the principal regulator of 
osteoclastogenesis; RANKL is produced by cells of osteoblastic lineage, and binds to its 
receptor, the receptor activator of nuclear factor-κB (RANK) expressed on the cell 
surface of osteoclast precursors, triggering key intracellular signaling cascades [14-17]. 
  Together with RANKL/RANK signaling, costimulatory signals mediated by 
immunoreceptor tyrosine-based activation motif (ITAM)-bearing adaptor proteins are 
required for the terminal differentiation of osteoclasts [18-20] (Fig 1). DNAX-activating 
protein of 12 kDa (DAP12) is one such ITAM-bearing adaptor; its deficiency is 
reportedly associated with skeletal abnormalities in mice and humans, suggesting the 
involvement of this signaling pathway in regulating osteoclast development and/or 
function [21-25]. ITAM-bearing adaptor proteins have minimal extracellular binding 
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domains and are thought to convey extracellular signals through interaction with 
ligand-binding, immunoglobulin-like receptors (IgLRs) (Fig 1). Triggering receptor 
expressed on myeloid cells 2, signal-regulatory protein β1, and myeloid 
DAP12-associating lectin-1 are IgLRs expressed on osteoclasts, and candidate 
DAP12-associating partners [18, 20, 25]. However, studies in mutant mice have not yet 
clarified the relevance of these genes in bone homeostasis, implying the existence of 
undiscovered DAP12-associated receptors critical for osteoclastogenesis. 
  As described above, extensive research has been clarifying the biology of osteoclasts 
on the molecular level, and based on these elucidated molecular mechanisms, various 
therapeutic agents have been developed which are effective for treating osteoporotic 
patients. However, as the molecular mechanisms regulating osteoclastogenesis are not 
fully understood, there still remains the possibility of existing undiscovered 
osteoclast-related molecules. When discovered, such molecules can be new targets for 
drug development which could fulfill the medical needs that are unmet by current 
osteoporosis therapies. I started the current studies in order to identify novel genes 
involved in osteoclastogenesis and to validate them as new molecular targets for 
anti-osteoporosis drugs. 
  As a result of in silico screening by using a human gene expression database, I found 
sialic acid-binding immunoglobulin-like lectin 15 (Siglec-15) to be one of the genes 
markedly overexpressed in giant cell tumor of bone which is a locally aggressive 
intraosseous neoplasm and is characterized by clinical findings of osteolytic bone 
destruction [26]. Siglec-15 is a newly identified member of the Siglec family of 
cell-surface IgLRs that recognizes sialylated glycan ligands [27-30]. The molecule 
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contains one N-terminal V-set immunoglobulin domain and one C2-set immunoglobulin 
domain in the extracellular region, and preferentially recognizes 
Neu5Acα2-6GalNAcα-structures (α(2,6)-linked sialic acid) through the V-set domain. 
Siglec-15 was reported as being expressed on macrophages and/or dendritic cells and is 
highly conserved throughout vertebrate evolution. In intracellular signaling, Siglec-15 
reportedly associates more avidly with DAP12 than other ITAM-bearing signaling 
adaptors, such as the DNAX-activating protein of 10 kDa or Fc receptor γ subunit, in 
293T cells co-transfected with constructs expressing these genes [29]. Although a 
certain regulatory role in the immune system has been suggested based on its gene 
expression in macrophages and/or dendritic cells [29], the physiological role of 
Siglec-15 in vertebrates remains unknown. 
  In Chapter 1, I demonstrate, based on the expression profiles and functional analysis 
using polyclonal antibody, that Siglec-15 is crucially involved in osteoclast 
differentiation in vitro. In Chapter 2, I discuss how I generated and analyzed 
Siglec-15-deficient mice to elucidate the physiological role of this gene in vivo, 
especially during osteoclastogenesis and skeletal development. Finally, in General 
Discussion, I describe the possibility of the development of a new drug targeting 
Siglec-15 for the treatment of osteoporosis, and what remains to be clarified in future 
studies in order to fully understand the physiological role of this molecule in the biology 
of osteoclasts.  
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Fig. 1. Current understanding of intracellular signaling required for the terminal 
osteoclast differentiation. RANKL/RANK signaling mediated by tumor necrosis factor 
receptor-associated factor 6 (TRAF6) and cFos induces expression of the nuclear factor 
of activated T-cells, cytoplasmic, calcineurin-dependent 1 (NFATc1), a key transcription 
factor for osteoclastogenesis. Together with RANKL/RANK signaling, costimulatory 
signals mediated by ITAM-bearing adaptor proteins are required for the terminal 
differentiation of osteoclasts. Upon binding to IgLRs, ITAM-bearing adaptors recruit 
Syk family kinases, leading to the activation of phospholipase Cγ (PLCγ) and calcium 
signaling, which is critical for NFATc1 activation. Syk downstream pathways other than 
PLCγ/calcium signaling are also important for the terminal osteoclast differentiation.  
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Chapter 1 
 
Identification of Siglec-15, a Member of the Sialic Acid-Binding Lectin, 
as a Novel Regulator for Osteoclast Differentiation 
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Summary 
  Osteoclasts are tartrate-resistant acid phosphatase (TRAP)-positive multinucleated 
cells derived from monocyte/macrophage-lineage precursors and are critically 
responsible for bone resorption. In giant cell tumor of bone (GCT), numerous 
TRAP-positive multinucleated giant cells emerge and severe osteolytic bone destruction 
occurs, implying that the emerged giant cells are biologically similar to osteoclasts. To 
identify novel genes involved in osteoclastogenesis, I searched genes whose expression 
pattern was significantly different in GCT from normal and other bone tumor tissues. 
By screening a human gene expression database, I identified sialic acid-binding 
immunoglobulin-like lectin 15 (Siglec-15) as one of the genes markedly overexpressed 
in GCT. The mRNA expression level of Siglec-15 increased in association with 
osteoclast differentiation in cultures of mouse primary unfractionated bone marrow cells 
(UBMC), RAW264.7 cells of the mouse macrophage cell line and human osteoclast 
precursors (OCP). Treatment with polyclonal antibody to mouse Siglec-15 markedly 
inhibited osteoclast differentiation in primary mouse bone marrow-derived 
monocyte/macrophage (BMM) cells stimulated with receptor activator of nuclear factor 
κB ligand (RANKL) or tumor necrosis factor-α (TNF-α). The antibody also inhibited 
osteoclast differentiation in cultures of mouse UBMC and RAW264.7 cells stimulated 
with active vitamin D3 and RANKL, respectively. Finally, treatment with polyclonal 
antibody to human Siglec-15 inhibited RANKL-induced TRAP-positive multinuclear 
cell formation in a human OCP culture. These results suggest that Siglec-15 plays an 
important role in osteoclast differentiation.  
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Introduction 
  Osteoclasts are bone-resorbing multinucleated cells generated from mononuclear 
monocyte/macrophage-lineage hematopoietic precursors. The receptor activator of 
nuclear factor κB ligand (RANKL) is the principal regulator of osteoclastogenesis, 
which binds to its receptor, the receptor activator of nuclear factor κB (RANK) 
expressed on the cell surface of osteoclast precursors, and induces osteoclast formation 
and activation [14-16]. This RANKL/RANK system is not only crucial for 
physiological osteoclast formation, but also implicated in the pathogenesis of diseases 
associated with enhanced osteoclastic bone resorption, which include bone destruction 
in rheumatoid arthritis, bone metastasis of cancer cells and metabolic bone diseases 
such as postmenopausal osteoporosis [31]. Therefore, it is quite rational to develop 
therapeutics for treating such disorders by suppressing osteoclastic bone resorption 
through inhibiting the RANKL/RANK system [32]. However, as the molecular 
mechanisms regulating osteoclastogenesis are not fully understood, there still remains 
the possibility of existing undiscovered osteoclast-related molecules which can be new 
targets for drug development. 
  Giant cell tumor of bone (GCT) is a locally aggressive intraosseous neoplasm and 
characterized by clinical findings of osteolytic bone destruction [26]. Its tumoral tissue 
consists of neoplastic stromal cells, mononuclear histiocytic cells and multinucleated 
giant cells. Although the origin of GCT is still incompletely understood, it is likely that 
an osteoclastogenic environment is formed in GCT, since RANKL and RANK have 
been reported to be overexpressed in the tumor [33-36]. In addition, a number of 
osteoclast-related genes have been reported to be overexpressed in GCT, including 
 - 14 - 
 
tartrate-resistant acid phosphatase (TRAP), multiple components of 
vacuolar-H+-ATPase and dendritic cell-specific transmembrane protein [36]. These 
findings suggest a biological similarity between giant cells that emerged in GCT and 
normal osteoclasts. 
  To identify genes involved in osteoclastogenesis and to discover novel drug targets 
for metabolic bone diseases, I searched genes whose expression level in GCT was 
significantly different from that in normal and other bone tumor tissues using a human 
gene expression database. The screening identified sialic acid-binding 
immunoglobulin-like lectin 15 (Siglec-15) as one of the genes markedly overexpressed 
in GCT. Siglec-15 is a newly identified member of the Siglecs, which are cell-surface 
receptors that recognize sialylated glycans [27-29]. Siglec-15 has been reported as being 
expressed on macrophages and/or dendritic cells and as being highly conserved 
throughout vertebrate evolution [29]. Although a certain regulatory role in the immune 
system has been suggested, the physiological role of Siglec-15 in the vertebrate remains 
unknown. To reveal relationship of this newly identified gene to osteoclastogenesis, I 
conducted in vitro studies using human and mouse osteoclast precursor cells. I 
demonstrated here, based on the expression profiles and functional analysis using 
polyclonal antibody, that Siglec-15 is crucially involved in osteoclast differentiation.  
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Materials and Methods 
In silico screening for GCT-related genes 
  The human gene expression database, BioExpress System (Gene Logic Division, 
Ocimum Biosolutions, Inc.), containing Affymetrix U133 GeneChip expression profiles 
of numerous human samples from more than 60 normal and diseased tissue types, was 
analyzed to identify genes specifically up- or down-regulated in GCT. The gene 
expression values for each probe set were retrieved from bone samples consisting of 
12 GCT samples, 10 tumor samples other than GCT and 7 normal samples using the 
BioExpress Web Export tool. Genes significantly (p < 0.05) up- or down-regulated in 
the GCT samples compared to the combined set of other tumors and normal samples 
were determined as GCT-related genes. These genes were further analyzed regarding 
Pearson's correlation (|r|>0.7) with RANK (Affymetrix ID: 207037_at) or RANKL 
(210643_at and 211153_s_at) in their expression values by using in-house Perl 
programs. The TMHMM program [37] was utilized to predict the topology of the gene 
products. 
 
Cell preparation and culture 
  Mouse bone marrow-derived monocyte/macrophage (BMM) cells were prepared 
according to the previously described method with slight modifications [18]. Briefly, 
bone marrow cells were flushed out from femurs and tibiae of male ddY mice (Japan 
SLC) and seeded to flasks. After being cultured overnight, non-adherent cells were 
collected and cultured in 96-well plates (3 × 10
4
 cells/well) in the presence of 5 ng/mL 
human macrophage colony-stimulating factor (M-CSF) (R&D Systems) for 2 days to 
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generate mouse BMM. Mouse primary unfractionated bone marrow cells (UBMC) were 
prepared from mouse femurs and tibiae. RAW264.7 cells were purchased from 
American Type Culture Collection. Mouse BMM, UBMC and RAW264.7 cells were 
cultured in α-MEM (Invitrogen) containing 10% fetal bovine serum, 100 μg/mL 
streptomycin and 100 U/mL penicillin. Poietics
 
Human Osteoclast Precursors (OCP) 
were cultured with OCP Basal Medium supplemented with 10% fetal bovine serum, 
2 mM L-glutamine, 100 μg/mL streptomycin and 100 U/mL penicillin (all from Lonza 
Walkersville) according to the manufacturer’s instructions.  
 
Quantitative RT-PCR 
  RAW264.7 cells were seeded at 4.5 × 10
5
 cells in 75-cm
2
 flasks, and cultured with or 
without 40 ng/mL human RANKL for 0–3 days. Mouse UBMC was seeded at 
5 × 10
5
 cells/well in 96-well plates, and cultured with or without 2 × 10
-8
 M active 
vitamin D3 (Sigma-Aldorich) for 8 days. Human OCP was seeded at 1 × 10
4
 cells/well 
in 96-well plates, and cultured in medium containing 33 ng/mL M-CSF with or without 
53.2 ng/mL RANKL for 3 days. The mRNA expression levels of GCT-related genes, 
cathepsin K, TRAP and ribosomal protein L32 as an endogenous reference were 
quantified by the real-time PCR method on a sequence detection system (ABI Prism 
7700; Applied Biosystems). Specific primers and probes were used for amplification of 
mouse genes including CD84 (forward, 5’-ACATGCTCTGTGGAAAAGGAAG-3’; 
reverse, 5’-GATGGAAGCTTGGAGTGTCTGT-3’; probe, 5’-TACAGCCCAGAACC 
CTGTCAGCAACAGT-3’), Siglec-15 (forward, 5’-TCAGGCTCAGGAGTCCAATT 
AT-3’; reverse, 5’-GGTCTAGCCTGGTACTGTCCTTT-3’; probe, 5’-ATTTGAGCCA 
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GATGAGTCCTCCAGGCCA-3’), multiple EGF-like-domains 10 (MEGF10) (forward, 
5’-CTCATCTGCTCACTGCTCTGTC-3’; reverse, 5’-GTAGCTGATTCTGTGCCGT 
GT-3’; probe, 5’-ACTGGGAAAGCTACTCGGTGACTGTGCA-3’), C-type lectin 
domain family 4, member A (CLEC4A) (forward, 5’-ATTCTGGCACAATGGTGA 
GC-3’; reverse, 5’-GAATGCCCATGAAGAATGAGTG-3’; probe, 5’-TTGGAAGACT 
GGATGGGGCTGGAACGA-3’), cathepsin K (forward, 5’-GGCATCTTTCCAGTTT 
TACAGC-3’; reverse, 5’-GTTGTTCTTATTCCGAGCCAAG-3’; probe, 5’-ATGTGA 
ACCATGCAGTGTTGGTGGTGGG-3’), TRAP (forward, 5’-GAACTTCCCCAGCCC 
TTACTAC-3’; reverse, 5’-AACTGCTTTTTGAGCCAGGAC-3’; probe, 5’-TTGCCA 
GTCAGCAGCCCAAAATGCCT-3’) and L32 (forward, 5’-AAGAAGTTCATCAGG 
CACCAGT-3’; reverse, 5’-CTTGACATTGTGGACCAGGAAC-3’; probe, 5’-AAAC 
CCAGAGGCATTGACAACAGGGTGC-3’). Specific primers and probes were used 
for amplification of human genes including cathepsin K (forward, 5’-CCGCAG 
TAATGACACCCTTT-3’; reverse, 5’-AAGGCATTGGTCATGTAGCC-3’; probe, 5’- 
TCAGGGTCAGTGTGGTTCCTGTTGGGCT-3’), TRAP (forward, 5’-CTGTCCTG 
GCTCAAGAAACA-3’; reverse, 5’-CCATAGTGGAAGCGCAGATA-3’; probe, 5’-TG 
AGAATGGCGTGGGCTACGTGCTGAGT-3’), Siglec-15 (forward, 5’-CAGCCACCA 
ACATCCATTTC-3’; reverse, 5’-CGCTCAAGCTAATGCGTGTA-3’; probe, 5’-AAGA 
ACAAAGGCCAGTGCGAGGCTTGGC-3’) and L32 (forward, 5’-GAGATCGCTCA 
CAATGTTTCCT-3’; reverse, 5’-GATGCCAGATGGCAGTTTTTAC-3’; probe, 5’-AC 
CGCAAAGCCATCGTGGAAAGAGCTG-3’). Samples were heated at 50°C for 2 min, 
95°C for 10 min and amplified for 40 cycles of 15 sec at 95°C and 1 min at 60°C. 
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Production of soluble Siglec-15 proteins 
  Two soluble forms of mouse Siglec-15 protein were produced by fusing the predicted 
extracellular domain of mouse Siglec-15 (amino acids 1-258) to the Fc region of human 
IgG1 or to a peptide containing a six-histidine tag. PCR was performed to amplify the 
extracellular domain of mouse Siglec-15 with the following two primers: 
5’-ggggacaagtttgtacaaaaaagcaggcttcaccATGGAGGGGTCCCTCCAACTC-3’ and 5’-gg 
ggaccactttgtacaagaaagctgggtcTCCGGGGGCGCCGTGGAAGCGGAAC-3’. The PCR 
product was then inserted into pDONR221 vector (Invitrogen) to generate an entry 
clone. Siglec-15-Fc or Siglec-15-His protein expression vectors were constructed by 
recombining the extracellular domain of Siglec-15 from the entry clone into destination 
vectors, which were designed to add the C-terminal Fc region of human IgG1 (232 
amino acids), or a six-histidine tag, respectively. These expression vectors were 
transfected into FreeStyle 293F cells (Invitrogen) for protein production. The expression 
of Siglec-15-Fc and Siglec-15-His proteins in the supernatant was checked by Western 
blotting using anti-Fc antibody (Sigma-Aldorich) and anti-hexahistidine antibody 
(Qiagen), respectively. Siglec-15-Fc in the supernatant was purified with a HiTrap 
Protein A column (GE Healthcare UK) and the purity of the protein was confirmed as a 
single 56.4-kDa protein band by SDS-PAGE and silver staining. Siglec-15-His in the 
supernatant was purified with a HisTrap HP column, followed by Resource Q column 
chromatography (all from GE Healthcare UK), and a protein fraction which was not 
absorbed onto the column was collected as the purified protein fraction. The purity of 
the protein was confirmed as a single 31-kDa protein band by silver staining. Soluble 
forms of human Siglec-15 were generated in the same way that the soluble forms of 
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mouse Siglec-15 were produced. To amplify the extracellular domain of human 
Siglec-15 (amino acids 1-260), PCR was performed with the following two primers: 
5’-ggggacaagtttgtacaaaaaagcaggcttcaccATGGAAAAGTCCATCTGGCTGC-3’ and 5’- 
ggggaccactttgtacaagaaagctgggtcCCCGCTGGCGCCATGGAAGCGG-3’. 
 
Anti-Siglec-15 polyclonal antibody 
  Rabbits were immunized by subcutaneous injection of a mixture of either mouse or 
human Siglec-15-Fc (100 or 50 μg, respectively) and oil adjuvant. The antiserum was 
applied to a HiTrap Protein A column to collect IgG proteins. Reactivity of the purified 
polyclonal antibody to Siglec-15 was confirmed by Western blotting analysis using both 
Siglec-15-Fc and Siglec-15-His proteins. Pre-immune rabbit IgG was purified from the 
serum, which was collected before immunization, with the same procedure as described 
above. The antibodies were further purified by affinity chromatography using the 
NHS-activated HiTrap column (GE Healthcare UK) immobilized with mouse or human 
Siglec-15-Fc. 
 
In vitro osteoclast formation assay 
  Mouse BMM in the 96-well plate was cultured in the presence of 10 ng/mL M-CSF 
with 20 ng/mL RANKL or 30 ng/mL human tumor necrosis factor-α (TNF-α) (R&D 
Systems) for 3 days. Mouse UBMC was seeded at 5 × 10
5
 cells/well in 96-well plates, 
and cultured in the presence of 2 × 10
-8
 M active vitamin D3 or 80 ng/mL RANKL for 
8 or 6 days, respectively. RAW264.7 cells were seeded at 4.5 × 10
3
 cells/well in 96-well 
plates, and cultured in the presence of 40 ng/mL RANKL for 3 days. Human OCP was 
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seeded at 1 × 10
4
 cells/well in 96-well plates, and cultured in the presence of 33 ng/mL 
M-CSF and 69 ng/mL RANKL for 5 days. During cultivation, cells were treated with 
anti-mouse or human Siglec-15 polyclonal antibody or pre-immune IgG. In the 
neutralization study, cells were treated with antigen-absorbed antibodies. Anti-mouse 
Siglec-15 polyclonal antibody was incubated with 1-, 3- and 10-fold higher 
concentrations of mouse Siglec-15-Fc or Siglec-15-His protein in Dulbecco's modified 
phosphate buffered saline containing 0.01% Tween 20 at 37°C for 2 h. After 
centrifugation, the supernatant of the mixture was collected as an antigen-absorbed 
antibody. TRAP activity assay and TRAP staining were employed to determine the 
effect on osteoclast formation. For the TRAP activity assay, cells were fixed with 
10% formaldehyde, and incubated in a 0.1 M acetate buffer (pH 5.0) containing 50 mM 
sodium tartrate and 15 mM p-nitrophenyl phosphate as a substrate (all from Wako Pure 
Chemical Industries) for 10–30 min at room temperature. The reaction was stopped by 
adding 1 N NaOH, and an absorbance at 405 nm was measured to determine the amount 
of p-nitrophenol as catabolite. TRAP staining was performed by incubating the fixed 
cells in 0.1 M acetate buffer (pH 5.0) containing 50 mM sodium tartrate, 
1% dimethylformamide (Wako Pure Chemical Industries), 0.27 mM naphthol AS-MX 
phosphate (Sigma-Aldorich) as a substrate and 1.6 mM Fast red violet LB salt 
(Sigma-Aldorich) as a stain for the reaction product for 5 min at room temperature. In 
the experiment using human OCP, TRAP-positive cells containing five or more nuclei 
were counted as multinuclear cells. 
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Statistical analysis 
  Welch’s t test and Wilcoxon’s rank sum test were used to identify GCT-related genes 
in in silico screening. A parametric Dunnett’s test was used to examine the differences 
in osteoclast formation assays. A probability (p-value) of < 0.05 was considered 
significant.  
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Results 
Identification of genes specifically up- or down-regulated in GCT 
  To identify GCT-related genes, I relied on the BioExpress System developed by Gene 
Logic, containing Affymetrix U133 oligonucleotide microarray expression profiles of 
numerous human samples from normal and diseased tissue types. The expression level 
of 10,259 probe sets was found to be significantly up- or down-regulated in GCT 
samples compared with those in normal and other tumor samples. To exclude genes 
which have less relationship with osteoclastogenesis, the probe sets were further 
examined to see if their expression pattern correlated with that of RANK and RANKL, 
both of which are known as key regulatory molecules in osteoclastogenesis [14-16]. The 
screening identified 709 probe sets whose expression levels were positively or 
negatively correlated with RANK or RANKL. These probe sets represented a set of 
genes that included known osteoclast marker genes, such as cathepsin K or TRAP 
(Table 1). Next, I utilized the TMHMM program in order to identify suitable drug 
targets from the selected 709 probe sets based on their predicted topology. CD84, 
Siglec-15, MEGF10 and CLEC4A were predicted to possess one transmembrane 
domain and considered as possible drug targets. In addition, the expression levels of 
these four genes were markedly up-regulated in GCT and highly correlated with those 
of RANK or RANKL (Table 1). I hypothesized that these genes were involved in 
osteoclastogenesis, and selected them as genes to be further examined. 
 
Expression of Siglec-15 and other GCT-related genes in osteoclasts 
  To examine the expression profiles of the selected four GCT-related genes in normal 
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osteoclastogenesis, I analyzed mRNA expression levels in osteoclasts prepared from 
mouse macrophage RAW264.7 cells treated with RANKL [38], and mouse UBMC 
treated with active vitamin D3 [39] (Table 2). The relative mRNA expression of CD84 
slightly increased (1.9-fold) by active vitamin D3 treatment in UBMC, while remained 
unchanged in RANKL-treated RAW264.7 cells. MEGF10 was not detected in either 
RAW264.7 cells or UBMC. CLEC4A expression remained unchanged or even 
decreased in osteoclasts differentiated from these cells. In contrast to these genes, the 
mRNA expression of Siglec-15 markedly increased in both RANKL-treated RAW264.7 
cells (13.8-fold) and active vitamin D3-treated UBMC (6.3-fold) compared with 
respective untreated cells. These results led me to speculate that Siglec-15 is the most 
probable gene involved in osteoclastogenesis, and to prioritize this gene for further 
examinations. 
  Next, I analyzed mRNA expression of Siglec-15 and a couple of osteoclast-specific 
genes, such as cathepsin K and TRAP in the course of osteoclast differentiation using 
RAW264.7 cells (Fig. 2). The expression of mRNA for Siglec-15 increased in a 
time-dependent manner from 2 days after RANKL stimulation. This expression pattern 
was closely related to those of osteoclast-specific genes, particularly to cathepsin K. The 
expression profile of Siglec-15 was further analyzed in a human osteoclast culture 
prepared from commercially available human OCP (Fig. 2). In a similar fashion to 
cathepsin K and TRAP, Siglec-15 expression was markedly up-regulated by RANKL 
stimulation in the cells. 
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Inhibitory effect of anti-Siglec-15 polyclonal antibody on osteoclast formation 
  To examine the functional role of Siglec-15 in osteoclast differentiation, I developed 
polyclonal antibodies for both mouse and human Siglec-15 and tested the effects of the 
antibodies in a variety of osteoclast culture systems. In primary mouse BMM culture 
system, which does not contain any adherent bone marrow cells such as stromal cells, 
anti-mouse Siglec-15 antibody decreased TRAP activity in cells stimulated with 
RANKL or TNF-α (Fig. 3A) in a concentration-dependent manner. The antibody also 
inhibited the increase in TRAP activity in a primary culture of mouse UBMC, which 
contains stromal or osteoblastic cells induced by active vitamin D3 treatment (Fig. 3A). 
These inhibitory effects on TRAP activity were not observed when the cells were 
treated with purified pre-immune IgG. TRAP staining demonstrated that anti-Siglec-15 
antibody treatment markedly inhibited RANKL-induced osteoclast differentiation from 
mouse UBMC to TRAP-positive multinuclear osteoclasts in comparison with 
pre-immune IgG-treated cells (Figs. 3B). 
  To confirm that the inhibitory effect of the antibody is mediated by Siglec-15 
recognition, anti-mouse Siglec-15 polyclonal antibody was absorbed with mouse 
Siglec-15 proteins conjugated with human Fc or hexahistidine tag and tested in mouse 
osteoclast culture systems. In mouse BMM culture, the inhibitory effect of 
anti-Siglec-15 antibody on TRAP activity was neutralized by absorption with its antigen 
(Fig. 3C). A similar result was obtained when RAW264.7 cells were treated with 
antigen-absorbed antibody (Fig. 3D). These results suggest that the inhibitory activity of 
the antibody on osteoclast formation is mediated by specific binding of the antibody to 
Siglec-15 protein expressed on the cells.  
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  Finally, I examined the effect of anti-human Siglec-15 polyclonal antibody on 
osteoclast formation from human OCP (Fig. 4). TRAP staining demonstrated that 
treatment with anti-Siglec-15 antibody inhibited multinuclear cell formation induced by 
RANKL in comparison with control or pre-immune IgG-treated cells. Quantitative 
analysis showed that the number of TRAP-positive multinuclear osteoclasts 
significantly decreased with anti-Siglec-15 antibody treatment.  
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Table 1 
Gene expression analysis in GCT. 
    Gene expression (Intensity)  Pearson correlation 
Gene name Affymetrix ID GCT  Normal/Other RANK RANKL 
RANK  207037_at 138 ± 37  16 ± 14  1.00 0.75 
RANKL  210643_at 194 ± 153 27 ± 23  0.75 1.00 
Cathepsin K 202450_s_at 8260 ± 3284 1843 ± 1379 0.81 0.84 
TRAP  204638_at 4600 ± 1099 507 ± 639 0.88 0.88 
CD84  205988_at 571 ± 272 128 ± 74  0.89 0.72 
Siglec-15  215856_at 623 ± 230 62 ± 38  0.84 0.73 
MEGF10  232523_at 1623 ± 1072 200 ± 169 0.71 0.79 
CLEC4A  219947_at 522 ± 200 62 ± 37  0.90 0.80 
 
  The expression levels of indicated genes in GCT were compared with those in normal 
and other tumor samples using the BioExpress database. The genes were further 
analyzed regarding Pearson's correlation with RANK and RANKL in their expression 
levels using in-house Perl programs. Gene expression data is expressed as the 
mean ± standard deviation (n = 12-17).  
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Table 2 
Relative mRNA expression levels of GCT-related genes in mouse osteoclasts. 
Gene name RAW264.7   UBMC 
  Control  RANKL Control  VD3 
CD84  0.0070  0.0075  0.17  0.33 
Siglec-15 0.0016  0.022  0.0015  0.0094 
MEGF10 ND  ND  ND  ND 
CLEC4A 0.042  0.028  0.026  0.022 
 
  Expression of mRNA was analyzed by real-time RT-PCR using mRNA for ribosomal 
protein L32 as an endogenous control. RAW264.7 was treated with or without 40 ng/mL 
RANKL for 3 days. UBMC was treated with or without 2 × 10
-8
 M active vitamin D3 
for 8 days. Data represents the value from one sample. ND: not detected.  
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Fig. 2. Siglec-15 mRNA expression during osteoclast differentiation. Expression of 
mRNA for cathepsin K, TRAP or Siglec-15 was analyzed by real-time RT-PCR using 
mRNA for ribosomal protein L32 as an endogenous control. Total RNA was extracted 
from RAW264.7 treated with or without 40 ng/mL RANKL for the indicated periods. 
Total RNA was extracted from human OCP treated with either 33 ng/mL M-CSF alone 
or in combination with 53.2 ng/mL RANKL for 3 days. Data represents the value from 
one sample.  
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Fig. 3A. Effect of anti-Siglec-15 antibody (Ab) on mouse osteoclast formation. Mouse 
BMM was treated with the indicated concentrations of anti-mouse Siglec-15 Ab or 
pre-immune IgG in the presence of 10 ng/mL M-CSF and either 20 ng/mL RANKL or 
30 ng/mL TNF-α for 3 days. Mouse UBMC was treated with antibodies in the presence 
of 2 × 10
-8
 M active vitamin D3 for 8 days. TRAP activity of the cells was measured as 
an indicator for osteoclast differentiation. Data represents the mean ± standard error 
(n = 3-6). *p < 0.05, **p < 0.01 and ***p < 0.001 compared with no treatment control 
cells. 
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Fig. 3B. Effect of anti-Siglec-15 antibody (Ab) on mouse osteoclast formation. TRAP 
staining was performed to determine the effect on osteoclast formation. Mouse UBMC 
was treated with 3.3 µg/mL anti-mouse Siglec-15 Ab or pre-immune IgG in the 
presence of 80 ng/mL RANKL for 6 days.  
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Figs. 3C and 3D. Neutralization of the effect of anti-Siglec-15 antibody (Ab) by its 
antigen. (C) Mouse BMM was treated with anti-mouse Siglec-15 Ab (0.5 μg/mL) 
absorbed or non-absorbed with its antigen in the presence of 10 ng/mL M-CSF and 
20 ng/mL RANKL for 3 days. TRAP activity of the cells was measured as an indicator 
for osteoclast differentiation. Data represents the mean ± standard error (n = 3). **p < 
0.01 and ***p < 0.001 compared with non-absorbed Ab-treated wells. (D) RAW264.7 
cells were treated with anti-mouse Siglec-15 Ab (1 μg/mL) absorbed or non-absorbed 
with its antigen in the presence of 40 ng/mL RANKL for 3 days, and stained for TRAP 
activity.  
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Fig. 4. Effect of anti-Siglec-15 antibody (Ab) on human osteoclast formation. Human 
OCP was treated with 30 μg/mL anti-human Siglec-15 Ab or pre-immune IgG in the 
presence of 33 ng/mL M-CSF and 69 ng/mL RANKL for 5 days. TRAP staining was 
performed to determine the effect on osteoclast formation. TRAP-positive multinuclear 
cells containing more than 5 nuclei were counted as mature osteoclasts. Data represents 
the mean ± standard error (n = 6). ***p < 0.001 compared with anti-Siglec-15 
Ab-treated wells. 
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Discussion 
  In order to discover novel drug target genes for metabolic bone diseases, I 
constructed a list of genes that were specifically up- or down-regulated in GCT utilizing 
the latest knowledge of bioinformatics. I thought that this was a rational approach since 
numerous osteoclast-like giant cells appear and severe resorptive bone destruction 
occurs in GCT [26]. Indeed, a number of osteoclast-related genes, such as cathepsin K 
and TRAP were included in the GCT-related gene list (Table 1). This confirmed the 
reliability of the list and I expected that the list contained some undiscovered 
osteoclast-related genes. I selected four candidates (CD84, Siglec-15, MEGF10 and 
CLEC4A) that were predicted to possess a single transmembrane domain from the 
GCT-related gene list. This kind of transmembrane protein is considered to be one of the 
potential druggable targets, and is relatively easy to analyze for its functionality by 
producing and using its recombinant soluble protein. Among the four selected 
candidates, only Siglec-15 gene expression was found to be up-regulated during normal 
osteoclast differentiation (Table 2). Although CD84 and MEGF10 have been reported to 
be overexpressed in GCT by other group as well [36], no clear correlation with 
osteoclast differentiation was observed in the present study. Though functional analysis 
would be required to elucidate their roles in osteoclastogenesis, these genes might be 
involved in tumorigenesis or expressed in cells other than those of an osteoclast-lineage 
in GCT. 
  Functional analysis using purified polyclonal antibody revealed that Siglec-15 is 
involved in both mouse and human osteoclastogenesis in vitro. In mouse culture 
systems, the extent of the inhibitory effect on TRAP activity varied in the culture 
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systems used. For example, anti-Siglec-15 antibody strongly inhibited the increase in 
TRAP activity in mouse BMM stimulated with RANKL, while moderate or partial 
inhibition was observed in BMM stimulated with TNF-α or in UBMC stimulated with 
active vitamin D3 (Fig. 3A). In contrast, anti-Siglec-15 antibody strongly inhibited 
TRAP-positive multinuclear cell formation in mouse UBMC, RAW264.7 and human 
OCP culture systems (Figs. 3B, 3D and 4). These results suggest that Siglec-15 may 
play a role mainly in osteoclast cell fusion, the terminal process in osteoclast 
differentiation. This hypothesis may be supported by the observation that Siglec-15 
expression pattern was closely related to that of cathepsin K, which is known as a late 
differentiation marker during osteoclastogenesis (Fig. 2).  
  In a recent publication, Takahata et al. reported that sialylation of cell surface 
glycoconjugates was required for proper osteoclast differentiation, especially for the cell 
fusion of osteoclast precursors [40]. As Siglec-15 was reported to recognize sialylated 
ligands [29], a direct functional link may be created between sialic acid recognition and 
the increasing expression of Siglec-15 in the differentiating osteoclasts, which may be 
required for proper osteoclastic cell fusion. It is also interesting to take into 
consideration that Siglec-15 associates with the activating adaptor molecule DNAX 
activation protein 12 (DAP12) [29], since DAP12 has been revealed to be critically 
involved in osteoclastogenesis as one of the key mediators of intracellular signals [18, 
20].  
  In this study, I identified Siglec-15 as a gene overexpressed in both GCT and normal 
osteoclasts. Functional analysis using polyclonal antibody suggested that Siglec-15 
plays an important role in osteoclast differentiation. These findings will provide new 
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opportunities for developing therapeutics targeting Siglec-15, such as antibody 
medication for the treatment of metabolic bone diseases.   
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Chapter 2 
Impaired Osteoclast Differentiation and Function and Mild 
Osteopetrosis Development in Siglec-15-deficient Mice 
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Summary 
  Sialic acid-binding immunoglobulin-like lectin 15 (Siglec-15) is a cell surface 
receptor for sialylated glycan ligands. In Chapter 1, I identified the upregulated Siglec15 
expression in differentiated osteoclasts and inhibition of osteoclast differentiation by 
anti-Siglec-15 polyclonal antibody, demonstrating Siglec-15 involvement in 
osteoclastogenesis in vitro. To discern the physiological role of Siglec-15 in skeletal 
development and osteoclast formation and/or function in vivo, I generated 
Siglec-15-deficient (Siglec15
−/−
) mice and analyzed their phenotype. The Siglec15
−/−
 
mice developed without physical abnormalities other than increased trabecular bone 
mass in lumbar vertebrae and metaphyseal regions of the femur and tibia, causing mild 
osteopetrosis. Histological analyses demonstrated that the number of osteoclasts present 
on the femoral trabecular bone of the mutant mice was comparable to that of the 
wild-type mice. However, urinary deoxypyridinoline, a systemic bone resorption marker, 
decreased in the Siglec15
−/−
 mice, indicating that impaired osteoclast function was 
responsible for increased bone mass in the mutant mice. In addition, the ability of bone 
marrow-derived monocyte/macrophage cells from the Siglec15
−/−
 mice to differentiate 
into osteoclasts was impaired, as determined in vitro by cellular tartrate-resistant acid 
phosphatase activity in response to the receptor activator of nuclear factor-κB ligand or 
tumor necrosis factor-α. These results reveal the importance of Siglec-15 in the 
regulation of osteoclast formation and/or function in vivo, providing new insights into 
osteoclast biology.  
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Introduction 
  Development and maintenance of the skeletal system depends on the balance between 
bone formation by osteoblasts and bone resorption by osteoclasts, and these opposing 
processes interact, forming a functional coupling [2, 41]. Osteoblasts, derived from 
mesenchymal stem cells, exist on the bone surface and synthesize bone matrix. In 
functional coupling, osteoblasts regulate osteoclast formation both by secreting factors, 
including macrophage colony-stimulating factor (M-CSF), interleukin-1 (IL-1), and 
IL-6 [11], and by direct interaction with osteoclast precursors [12, 13]. Conversely, 
osteoclasts are multinucleated cells positive for tartrate-resistant acid phosphatase 
(TRAP) generated from mononuclear monocyte/macrophage lineage hematopoietic 
precursors [10], which resorb bone by secreting protons and proteases into resorption 
zones. Accordingly, mice carrying mutated genes responsible for osteoclast formation 
and/or function exhibit increased bone mass (osteopetrotic phenotype) caused by 
impaired bone resorption [42, 43]. During osteoclastogenesis, the receptor activator of 
nuclear factor-κB ligand (RANKL)—produced by cells of osteoblastic lineage—binds 
to its receptor, receptor activator of nuclear factor-κB (RANK)—expressed on the cell 
surface of osteoclast precursors—triggering key intracellular signaling cascades [15, 16, 
44].
 
  Together with RANK/RANKL signaling, costimulatory signals mediated by 
immunoreceptor tyrosine-based activation motif (ITAM)-bearing adaptor proteins are 
required for the terminal differentiation of osteoclasts [18-20]. DNAX-activating protein 
of 12 kDa (DAP12) is one such ITAM-bearing adaptor; its deficiency is reportedly 
associated with skeletal abnormalities in mice and humans, suggesting the involvement 
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of this signaling pathway in regulating osteoclast development and/or function [21-25]. 
ITAM-bearing adaptor proteins have minimal extracellular binding domains and are 
thought to convey extracellular signals through interaction with ligand-binding, 
immunoglobulin-like receptors (IgLRs). Triggering receptor expressed on myeloid cells 
2 (TREM-2), signal-regulatory protein β1, and myeloid DAP12-associating lectin-1 are 
IgLRs expressed on osteoclasts, and candidate DAP12-associating partners [18, 20, 25]. 
However, studies in mutant mice have not yet clarified the relevance of these genes in 
bone homeostasis, implying the existence of undiscovered DAP12-associated receptors 
critical for osteoclastogenesis. 
  Sialic acid-binding immunoglobulin-like lectin 15 (Siglec-15) is a newly identified 
member of the Siglec family of cell-surface IgLRs that recognizes sialylated glycan 
ligands [27-29]. Siglec-15 reportedly associates more avidly with DAP12 than other 
ITAM-bearing signaling adaptors, such as the DNAX-activating protein of 10 kDa or Fc 
receptor γ subunit (FcRγ), in 293T cells co-transfected with constructs expressing these 
genes [29]. Although a certain regulatory role in the immune system has been suggested 
based on its gene expression in macrophages and/or dendritic cells [29], the 
physiological role of Siglec-15 in vertebrates remains unknown. In Chapter 1, I 
demonstrated that Siglec15 expression was upregulated during osteoclast differentiation 
in mouse and human osteoclast culture systems. Moreover, functional analysis using a 
polyclonal antibody against Siglec-15, demonstrated an inhibitory effect on osteoclast 
formation in vitro, suggesting that Siglec-15 is critical to osteoclastogenesis. To 
elucidate the physiological role of this gene in vivo, especially during osteoclastogenesis 
and skeletal development, I generated Siglec-15-deficient (Siglec15
−/−
) mice and 
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analyzed their phenotype.  
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Materials and Methods 
Gene targeting and generation of Siglec15
−/−
 mice 
  Genomic clones encoding the Siglec15 locus were isolated from a 129S6/SvEvTac 
mouse bacterial artificial chromosome library by screening with a radiolabeled DNA 
fragment of a 550-base pair region of exon 1. A targeting vector was constructed by 
replacing exons 2–4, encoding two immunoglobulin-like domains and a transmembrane 
domain, with a phosphoglycerate kinase neomycin resistance cassette. The linearized 
targeting vector was electroporated into 129 Sv/EvTac-derived embryonic stem cells. 
G418-resistant colonies were genotyped by PCR and genomic Southern blot analyses to 
identify clones carrying a targeted allele. Targeted cells were injected into C57BL/6 
blastocysts, and transferred into pseudopregnant female ICR mice. Resulting chimeric 
males were bred with C57BL/6 females; heterozygous offspring were then backcrossed 
to the C57BL/6 strain for 7–8 generations by in vitro fertilization. Following 
heterozygous matings of backcrossed animals, the Siglec15
−/−
 mice were identified by 
Southern blot analysis of genomic DNA cut with KpnI using a specific probe. All 
procedures described here were performed at PhoenixBio Co., Ltd. 
 
Animal experiments 
  Experimental procedures were performed in accordance with the in-house guidelines 
of the Institutional Animal Care and Use Committee of Daiichi Sankyo Co., Ltd. 
Seven-week-old male and female Siglec15
−/−
 mice and their wild-type littermates were 
obtained from PhoenixBio Co., Ltd. The animals were fed a normal diet and given tap 
water ad libitum under a controlled room temperature and humidity. Whole-body 
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microradiographs were performed using a μFX-1000 radiography system (Fujifilm) and 
BAS-2500 imaging system (Fujifilm) on anesthetized mice 4 days before necropsy. 
Body weight was measured 1 day before necropsy. 
  At 18 weeks of age, the mice were euthanized by exsanguination after collecting 
blood samples from the inferior vena cava under anesthesia. Whole blood samples were 
used for hematological and blood chemical analyses. Lumbar vertebrae, femurs, and 
tibiae were excised for bone phenotypic analysis. Thoracic and abdominal organs were 
observed macroscopically, and the liver, thymus, spleen, and testes were weighed. The 
following organs/tissues were histopathologically examined: sternum (bone marrow), 
thymus, lung, heart, mesenteric lymph node, liver, spleen, kidney, adrenal gland, 
pancreas, stomach, duodenum, jejunum, ileum, cecum, colon, rectum, thyroid 
(including parathyroid), testis (male), ovary (female), uterus (female), tibia (bone 
marrow), eye, and skin (dorsal region). Testes were fixed with FSA, eyes with 
Davidson’s fixative, and other organs/tissues with 10% neutral-buffered formalin. After 
fixation, histopathological sections were prepared and stained with hematoxylin and 
eosin. 
 
Bone densitometry and micro-CT imaging 
  After removing connective tissue, excised lumbar vertebrae (L3–6) and paired femurs 
were defatted and dehydrated by ethanol treatment, with subsequent air seasoning. 
  Areal bone mineral density of the lumbar vertebrae and femurs was measured by 
dual-energy X-ray absorptiometry using a DCS-600EX-IIIR (Aloka) optimized for 
small bone specimens. The scan speed was 25 mm/s, and scan width was 1 mm. Bone 
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mineral density analysis was performed based on single energy (22 keV) X-ray 
absorption data for lumbar vertebrae L3–6 and 20 equally divided femoral regions. 
  Right femoral volumetric bone mineral content (vBMC) was measured by peripheral 
quantitative computed tomography (pQCT) using XCT Research SA+ (Stratec 
Medizintechnik) and XCT6.20 analyzing software (Stratec Medizintechnik) at ELK 
Corporation. Two slices were measured with an 80 × 80 × 460 μm voxel size at 2 mm 
proximal to the distal femoral growth cartilage for trabecular regions and the femoral 
midpoint for cortical regions. Trabecular bone in the metaphysis and cortical bone in the 
diaphysis were analyzed with contour mode 2, with peel mode 20 (trabecular area 35%), 
and contour mode 1 using a threshold of 690 mg/cm
3
, respectively. 
  Micro-computed tomography (micro-CT) imaging of the fifth lumbar vertebra was 
performed using ScanXmate-L080H (Comscantecno), with a voxel size of 14 μm in 
three dimensions. Three-dimensional images were reconstructed using bone structural 
analysis software, TRI/3D-BON (RATOC System Engineering). 
 
TRAP staining of bone 
  Right tibiae were excised and fixed in cold 70% ethanol. Processing of bone 
specimens was performed at Kureha Special Laboratory Co., Ltd. Proximal tibiae were 
dehydrated in graded ethanol concentrations and embedded in glycol methacrylate 
(Wako Pure Chemical Industries) without decalcification. Frontal plane sections (3 μm 
thick) of the proximal metaphysis were prepared using an RM2255 rotary microtome 
(Leica Microsystems, Germany) and stained for TRAP activity using a method adapted 
from that previously described [45]. Hematoxylin and eosin staining was performed 
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using histopathological sections of tibiae fixed with 10% neutral-buffered formalin. 
 
Bone histomorphometry 
  Mice were subcutaneously injected with calcein (20 mg/kg; Dojindo) and tetracycline 
hydrochloride (20 mg/kg; Sigma-Aldrich) 7 and 3 days prior to dissection, respectively. 
At necropsy, right femurs were excised and fixed in 70% ethanol, and adherent muscle 
was removed. Bone specimen processing and histomorphometry in cortical and 
cancellous bone were performed at Ito Bone Histomorphometry Institute. Distal and 
central femurs were stained with Villanueva bone stain for 5 days, dehydrated in graded 
ethanol concentrations, and embedded in methyl methacrylate (Wako Pure Chemical 
Industries) without decalcification. For cancellous bone histomorphometry, frontal plane 
sections (5 μm thick) of the distal metaphysis were prepared using the RM2255 rotary 
microtome. The region of interest was located 0.25 mm–1.00 mm proximal to the distal 
femoral growth cartilage/metaphyseal junction, and 0.25 mm from the endosteal border 
of the cortices. Measurements were collected at 400× magnification using the 
semiautomatic image analyzing system, Histometry RT (System Supply), linked to a 
BX-51 light/epifluorescent microscope (Olympus). The following parameters were 
measured: bone volume per total tissue volume, trabeculae number, and osteoblast 
surface, osteoclast surface, and bone formation rate per unit bone surface. Cortical bone 
histomorphometry was performed on femoral midpoint cross-sections ground to a 10- to 
20-μm-thickness using a Speed Lap ML-521 (Maruto Instrument). Cortical area, osteoid 
surface, eroded surface, and labeled surface were measured per unit periosteal bone 
surface. Standard bone histomorphometric nomenclature, symbols, and units were used 
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according to the American Society of Bone and Mineral Research Histomorphometry 
Nomenclature Committee [46]. 
 
Measurement of bone metabolic markers 
  Urine samples were collected by gently pushing the abdomen of 9- and 18-week-old 
animals. Urinary deoxypyridinoline (DPD) excretion was measured using an 
enzyme-linked immunosorbent assay kit from DS Pharma Biomedical Co., Ltd. To 
compensate for individual variation in DPD excretion, urinary creatinine concentration 
was also measured using an assay kit (Kainos) according to the manufacturer’s 
instructions. Serum samples prepared at necropsy were used to measure levels of the 
bone formation marker, osteocalcin (Mouse Osteocalcin EIA kit; Biomedical 
Technologies). A microplate reader, SpectraMax 250 (Molecular Devices), was used for 
each assay. 
 
in vitro osteoclast formation assay 
  Mouse bone marrow-derived monocyte/macrophage (BMM) cells were prepared 
according to previously described methods, with slight modifications [18]. In brief, 
bone marrow cells were flushed from femurs and tibiae of the 10-week-old male 
Siglec15
−/− 
or wild-type mice, and seeded to flasks with α-MEM (Life Technologies), 
containing 5 ng/mL human M-CSF (R&D Systems), 10% fetal bovine serum, 
100 μg/mL streptomycin, and 100 U/mL penicillin. After being cultured overnight, 
nonadherent cells were collected and suspended at 1.5 × 10
5
 cells/mL in medium 
containing 10 ng/mL human M-CSF alone for the RANKL-induced osteoclast 
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formation assay, or human M-CSF in combination with 2 ng/mL human transforming 
growth factor-β (R&D Systems) for the tumor necrosis factor-α (TNF-α)-induced assay. 
The cells were then seeded in 96-well plates (0.2 mL/well), and cultured for 2 days to 
generate mouse BMM. After replacing old medium with fresh medium, cells were 
cultured in medium containing 10 ng/mL M-CSF, and 30 ng/mL human RANKL 
(PeproTech) or 30 ng/mL human TNF-α (R&D Systems) for an additional 4 days. For 
the TRAP activity assay, cells were solubilized with 50 μL of 50 mM sodium citrate 
buffer (pH 6.1) containing 1% Triton X-100, and incubated with 50 μL of 50 mM 
sodium citrate buffer (pH 6.1), containing 5 mg/mL p-nitrophenyl phosphate 
(Sigma-Aldrich) and 0.46% sodium tartaric acid, for 20 min at room temperature. The 
reaction was stopped by adding 50 μL of 1 N NaOH, and an absorbance at 405 nm was 
measured using a SpectraMax 250 to determine the amount of p-nitrophenol as a 
catabolite.  
 
Statistical analysis 
  Mean and standard error were calculated using Excel 2003. All statistical analyses 
were conducted using an in-house program, based on SAS System, Release 8.2, SAS 
Institute. Comparison between the wild-type and Siglec15
−/−
 littermates was performed 
by the F-test of variance, followed by Student’s t-test (homogeneous variance) or 
Welch’s t-test (non-homogeneous variance). A p value of <0.05 was considered 
significant.  
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Results 
Generation of Siglec15
−/−
 mice 
  To disrupt Siglec-15 in mice, I designed a targeting vector to replace exons 2–4 with a 
neomycin resistance cassette (Figs. 5A, 5B), deleting most of the extracellular and 
transmembrane domains of the Siglec-15 protein. Southern blot analysis of 4-week-old 
offspring of heterozygous matings revealed that the Siglec15
−/− 
mice were born in 
approximately Mendelian ratios (+/+: 149 [27%]; +/−: 280 [51%]; −/−: 118 [22%]). The 
Siglec15
−/−
 mice grew normally, without apparent physical abnormalities except for 
skeletal changes, according to body weight, hematology, blood chemistry, and 
pathological examinations performed on organs and tissues from 18-week-old mice, as 
described in the Materials and Methods. Although high Siglec-15 mRNA expression 
was reported in the human spleen, testis, and small intestine [29], histopathological 
examinations detected no obvious abnormalities in these organs in the Siglec15
−/−
 mice.
 
 
Mild osteopetrotic phenotype in Siglec15
−/−
 mice 
  To analyze the phenotypic changes in skeletal tissues, I performed radiography and 
bone densitometry on 18-week-old Siglec15
−/−
 mice. Whole body radiography 
demonstrated that the skeletal phenotype in mutant mice resembled to that in the 
wild-type mice (Fig. 6A), without profound osteopetrotic hallmarks, such as long bone 
shortening or tooth eruption failure [47-49]. However, increased bone density was 
evident, especially in the distal femur and proximal tibia of the Siglec15
−/−
 mice 
(Fig. 6B). Measurement of areal bone mineral density confirmed this quantitatively, 
showing a marked increase, especially from the distal metaphysis to the midshaft of the 
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femur (Fig. 6C). In addition, pQCT demonstrated profoundly increased trabecular 
vBMC in the distal femoral metaphysis in the Siglec15
−/−
 mice (Fig. 6D). Increased 
vBMC was also observed in the cortical bone of the femoral diaphysis in the female 
mutant mice, although the increase was slight compared with that in trabecular bone. No 
vBMC increase was evident in the cortical bone of the male mutant mice, suggesting 
sexual dimorphism of the cortical bone phenotype. Next, I performed micro-CT 
imaging of lumbar vertebrae to observe the phenotype at sites other than long bones. 
Trabecular bone mass was markedly increased in the fifth lumbar vertebra of the 
Siglec15
−/−
 mice compared with the wild-type mice (Fig. 6E), consistent with areal bone 
mineral density of lumbar vertebrae L3–6 (Fig. 6F). 
 
Histological and histomorphometrical analyses of the bone in Siglec15
−/−
 mice 
  I performed histological examinations on the hind limbs of the mutant mice to 
confirm an osteopetrotic phenotype and analyze morphological, quantitative, and 
dynamic changes in trabecular and cortical bone. Hematoxylin and eosin staining of 
longitudinal sections of the proximal metaphyseal tibia showed increased trabeculae 
number and trabecular bone volume, especially in the secondary spongiosa and 
epiphyseal ossification center, in the Siglec15
−/−
 mice (Fig. 7). No obvious histological 
changes were observed in the proximal tibial growth plate, consistent with the normal 
skeletal growth in the Siglec15
−/−
 mice (Fig. 6A). Despite increased bone mass, 
osteoclasts were detected by TRAP staining at primary and secondary spongiosa in the 
Siglec15
−/−
 mice, comparable to the wild- type mice (Fig. 7). In addition, bone 
histomorphometry of the distal femur demonstrated profound increases in both 
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trabecular bone volume per total tissue volume and trabeculae number, but no 
substantial changes in the percentage osteoclast surface per unit bone surface (Table 3). 
With regard to bone formation, osteoblast surface per unit bone surface and the bone 
formation rate per unit bone surface were markedly reduced in the Siglec15
−/−
 mice 
compared with the wild-type mice, suggesting that trabecular bone turnover was 
suppressed in the Siglec15
−/−
 mice. In cortical bone, the cortical area was slightly higher 
in the female mutant mice than in the wild-type mice, while no difference was evident 
in male mice, consistent with the pQCT-determined vBMC of the femoral diaphysis 
(Fig. 6D). In the female mutant mice, reduced eroded surface per unit periosteal bone 
surface and increased calcein- or tetracycline-labeled periosteal surface were evident, 
suggesting reduced bone resorption and enhanced bone formation. Conversely, in the 
male mutant mice, there were no clear changes in these parameters. Osteoid surface per 
unit periosteal bone surface did not change in the male or female mutant mice. 
 
Changes in bone metabolic markers in Siglec15
−/−
 mice 
  To assess systemic bone turnover in the mutant mice, urinary DPD excretion and 
serum osteocalcin levels were measured as markers of bone resorption and formation, 
respectively. Urinary DPD excretion in both male and female mutant mice decreased 
compared with the wild-type mice at 9 and 18 weeks of age (Fig. 8A), indicating that 
overall bone resorption activity was reduced in the Siglec15
−/−
 mice. Conversely, at 
18 weeks of age, osteocalcin levels were comparable in the male mutant mice and 
higher in the female mutant mice (Fig. 8B). 
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Impaired differentiation of Siglec15
−/−
 bone marrow-derived monocyte/macrophage 
cells into osteoclasts in vitro 
  I evaluated developmental differences in osteoclasts, induced in vitro from BMM of 
the wild-type and Siglec15
−/−
 mice by RANKL or TNF-α stimulation in the presence of 
M-CSF [18, 50]. Cellular TRAP activity, a marker of osteoclast differentiation, was 
upregulated in BMM from the wild-type mice by both RANKL and TNF-α treatment 
(Fig. 9). Although TRAP activity was upregulated in Siglec15
−/−
 BMM, it was lesser 
than that in the wild-type cells in both osteoclast formation culture systems. These 
results indicate that osteoclast differentiation is impaired, at least in vitro, by Siglec-15 
deficiency.  
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Fig. 5. Generation of Siglec15
−/−
 mice. (A) Schematic representation of the wild-type 
and targeted alleles at the Siglec15 locus. Exons, represented by black boxes, are 
numbered. The phosphoglycerate kinase neomycin resistance cassette (PGK-neo) 
replaced the genomic region containing exons 2–4, encoding two immunoglobulin-like 
domains and a transmembrane domain of Siglec-15. An unfilled box indicates the probe 
for Southern blot analysis. K, KpnI. (B) Southern blot analysis of offspring derived from 
heterozygous matings. Genomic DNA from the wild-type (+/+), heterozygous (+/−), 
and homozygous (−/−) Siglec-15-deficient mice were digested with KpnI and 
hybridized with the probe. DNA fragments’ sizes are indicated.  
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Figs. 6A and 6B. Representative radiographs of 18-week-old female wild-type and 
Siglec15
−/−
 mice. (A) Whole body radiographs and (B) magnified pictures of the left 
hind limb of the indicated mice. Arrows in the Siglec15
−/−
 mouse indicate increased 
radiodensity.  
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Figs. 6C and 6D. Increased bone mass in long bones in Siglec15
−/−
 mice. (C) Areal bone 
mineral density (aBMD) was measured in 20 longitudinal divisions of femurs from the 
female wild-type and Siglec15
−/−
 mice by dual-energy X-ray absorptiometry. (D) 
Volumetric bone mineral content (vBMC) of trabecular and cortical bone was analyzed 
by peripheral quantitative computed tomography at 2 mm proximal to the distal femoral 
growth cartilage and femoral midpoint, respectively. Data represent the mean ± standard 
error from the 18-week-old male wild-type (n = 10), male Siglec15
−/−
 (n = 7), female 
wild-type (n = 10) or female Siglec15
−/−
 mice (n = 9). *p < 0.05, **p < 0.01 and 
***p < 0.001 compared with the wild-type mice of same sex.  
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Figs. 6E and 6F. Increment in bone volume at lumbar vertebrae of Siglec15
−/−
 mice. (E) 
Representative three-dimensional micro-computed tomography images of the fifth 
lumbar vertebrae of the 18-week-old female wild-type and Siglec15
−/−
 mice. Scale bar: 
500 µm. (F) aBMD was measured in the lumbar vertebrae L3–6 from the wild-type and 
Siglec15
−/−
 mice. Data represent the mean ± standard error from the 18-week-old male 
wild-type (n = 10), male Siglec15
−/−
 (n = 7), female wild-type (n = 10) or female 
Siglec15
−/−
 mice (n = 9). ***p < 0.001 compared with the wild-type mice of same sex.  
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Fig. 7. Histologic evaluation of bone morphology in Siglec15
−/− 
mice. (Left panels) 
Hematoxylin and eosin staining of the proximal metaphysis of the right tibiae from the 
18-week-old female wild-type and Siglec15
−/−
 mice. Scale bar: 1 mm. (Right panels) 
Magnified pictures of the primary spongiosa of proximal tibiae stained for TRAP 
activity to visualize osteoclasts in red. Scale bar: 100 µm.  
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Table 3 
Bone histomorphometrical analysis of femurs in wild-type and Siglec15
−/−
 mice. 
Parameters   Wild-type  Siglec15
−/−
 
Male   
Distal femoral metaphysis 
(cancellous bone)   
BV/TV (%)   9.66 ± 0.65  20.58 ± 2.19
b
 
  Tb.N (#/mm)   3.49 ± 0.15  8.09 ± 0.97
b
 
  Ob.S/BS (%)   19.18 ± 1.16  6.71 ± 1.05
c
 
  Oc.S/BS (%)   7.702 ± 0.528  7.255 ± 0.860 
  BFR/BS (mm
3
/mm
2
/y)  0.1492 ± 0.0100  0.0297 ± 0.0034
c
 
   
Femoral midshaft 
(cortical bone)   
  Ct.Ar (mm
2
)   0.8348 ± 0.0262  0.8537 ± 0.0101 
  Ps.OS/Ps.BS (%)  24.90 ± 2.60  25.65 ± 2.94 
  Ps.ES/Ps.BS (%)   14.98 ± 3.24  22.75 ± 3.09 
  Ps.LS/Ps.BS (%)   43.40 ± 1.83  37.99 ± 3.97 
   
Female   
Distal femoral metaphysis 
(cancellous bone)   
  BV/TV (%)   6.21 ± 0.60  24.62 ± 1.74
c
 
  Tb.N (#/mm)   2.29 ± 0.17  7.71 ± 0.72
c
 
  Ob.S/BS (%)   42.80 ± 2.52  13.34 ± 1.24
c
 
  Oc.S/BS (%)   9.263 ± 1.002  8.646 ± 0.421 
  BFR/BS (mm
3
/mm
2
/y)  0.3475 ± 0.0079  0.0776 ± 0.0094
c
 
   
Femoral midshaft 
(cortical bone)   
  Ct.Ar (mm
2
)   0.8326 ± 0.0145  0.9056 ± 0.0114
b
 
  Ps.OS/Ps.BS (%)  37.03 ± 2.77  38.69 ± 3.71 
  Ps.ES/Ps.BS (%)   21.88 ± 2.66  7.58 ± 1.31
c
 
  Ps.LS/Ps.BS (%)   46.82 ± 3.39  59.09 ± 3.36
a
 
 
BV/TV: bone volume/tissue volume; Tb.N: trabecular number; Ob.S/BS: osteoblast 
surface/bone surface; Oc.S/BS: osteoclast surface/bone surface; BFR/BS: bone 
formation rate/bone surface; Ct.Ar: cortical area; Ps.OS/Ps.BS: periosteal osteoid 
surface/bone surface; Ps.ES/Ps.BS: periosteal eroded surface/bone surface; 
Ps.LS/Ps.BS: labeled periosteal surface/bone surface. Data represent the 
mean ± standard error from 18-week-old male wild-type (n = 8), male Siglec15
−/−
 
(n = 8), female wild-type (n = 6) or female Siglec15
−/−
 mice (n = 9). 
a
p < 0.05, 
b
p < 0.01, 
and 
c
p < 0.001 compared with wild-type mice.  
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Fig. 8. Changes in bone turnover markers in Siglec15
−/−
 mice. (A) Urine samples were 
collected from the wild-type and Siglec15
−/−
 mice at 9 and 18 weeks of age. Urinary 
deoxypyridinoline (DPD) excretion was measured, and adjusted for creatinine (Cre) 
concentration. (B) Serum levels of osteocalcin were determined with samples prepared 
from the 18-week-old wild-type and Siglec15
−/−
 mice. Data represent the 
mean ± standard error from the male wild-type (n = 10), male Siglec15
−/−
 (n = 7), 
female wild-type (n = 10), and female Siglec15
−/−
 mice (n = 9), with the exception of 
urinary DPD excretion at 9 weeks of age, where male wild-type (n = 9), and male 
Siglec15
−/−
 (n = 5). *p < 0.05, **p < 0.01, and ***p < 0.001 compared with the 
wild-type mice of the same sex.  
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Fig. 9. Osteoclast formation assay using bone marrow-derived monocyte/macrophage 
cells derived from the wild-type and Siglec15
−/−
 mice. Bone marrow-derived 
monocyte/macrophage cells were prepared from the 10-week-old male wild-type and 
Siglec15
−/−
 mice. Cells were cultured with 30 ng/mL RANKL, or 30 ng/mL TNF-α, for 
4 days in the presence of 10 ng/mL M-CSF. TRAP activity was measured as an indicator 
of osteoclast differentiation. Data represent the mean ± standard error (n = 12) from one 
experiment. ***p < 0.001 compared with wild-type cells.  
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Discussion 
  Osteopetrosis is a heterogeneous group of heritable genetic diseases, characterized by 
increased bone mass due to defective osteoclastic bone resorption [42, 43]. In mice, 
many genes associated with increased bone mass have been identified by mutant studies, 
revealing that osteopetrosis severity depends on genes functional in osteoclast 
differentiation and/or function. Osteopetrosis in the Siglec15
−/−
 mice was mild 
compared with, for example, c-Fos or RANK knockout mice, which exhibit a severe 
osteopetrotic phenotype, including long bone shortening and tooth eruption failure 
[47-49]. My observations suggest Siglec-15 deficiency causes partial reduction of bone 
resorption, leading to mild osteopetrosis in vivo. Reduced bone resorption was evident 
from lower urinary DPD excretion, while trabecular bone mass increased, despite 
comparable osteoclast numbers on femoral and tibial trabecular bone. These findings 
suggest that impaired osteoclast function, but not reduced osteoclast number, underlies 
the osteopetrotic phenotype of the Siglec15
−/−
 mice. These observations support 
development of therapies suppressing the Siglec-15 function to treat bone loss diseases, 
such as osteoporosis. In addition, a phenotype restricted to skeletal tissues may mean 
such therapies have fewer adverse effects on other organs or tissues. 
  In femoral trabecular bone, both osteoblast surface and bone formation rate per unit 
bone surface were reduced by Siglec-15 deficiency, indicating a possible role of the 
gene in osteoblast regulation as well. However, preliminary RT-PCR examinations 
detected no Siglec-15 expression in murine osteoblast lineage cells, such as ST2 and 
MC3T3-E1, even when they were cultured under differentiation-inducing conditions. In 
addition, anti-Siglec-15 antibody, which has a potential to inhibit osteoclast 
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differentiation, did not affect osteoblastic differentiation in vitro when determined by 
alkaline phosphatase activity in the cells. Although I need to assess the osteogenic 
capacity of Siglec15
−/−
 osteoprogenitor cells to make a conclusion, those preliminary 
results suggest a low possibility of a direct involvement of Siglec-15 in osteoblast 
regulation. Instead, reduction in osteoblast number and the bone formation rate 
observed in the Siglec15
−/−
 mice could be accounted for by considering the secondary 
effect resulting from reduced bone resorption based on the functional coupling concept 
in bone formation and resorption. 
  Although the osteopetrotic phenotype of trabecular bone was similar in the male and 
female Siglec15
−/−
 mice, increased bone mass was detected by pQCT and 
histomorphometrical analyses in cortical bone of the femoral midshaft in the female 
mice. Interestingly, femoral labeled periosteal surface per unit bone surface increased in 
the female mutant mice, suggesting that enhanced bone formation partly contributes to 
increased cortical bone mass. Increased serum osteocalcin levels in the female 
Siglec15
−/−
 mice support this idea, as approximately 80% of bone in the entire body 
comprises cortical bone [51]. However, enhanced cortical bone formation provokes a 
further question when contrasted with trabecular bone, where osteoblast surface and 
bone formation rate were reduced. I do not know why morphological changes in cortical 
bone differed between male and female mutant mice, nor why bone formation differed 
between femoral trabecular and cortical bone in female mutants. The molecular 
mechanisms responsible for the bone-sparing effects of sex steroids (estrogens and 
androgens) vary as a function of gender, skeletal site, and bone compartment [52, 53], 
which could provide insight into these differences. 
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  Siglec-15 reportedly associates with the DAP12 adaptor molecule [29], deficiency of 
which in mice is known to cause mild osteopetrosis [24, 25]. Comparing the skeletal 
phenotype in the Siglec15
−/−
 mice with DAP12-deficient (DAP12
−/−
) mice, we find 
many similarities. Both mutant mice grow normally without gross skeletal abnormalities, 
while exhibiting markedly increased trabecular bone. Micro-CT and histological images 
of trabecular bone in the two mutants are very alike. Another commonality is that the 
impact of genetic deficiency on osteoclast development differs in vivo and in vitro. 
Reportedly, osteoclast number and morphology in the DAP12
−/−
 mice were not 
significantly different from wild type mice, while impaired osteoclast formation was 
evident in vitro [24]. Similarly, in the Siglec15
−/−
 mice, TRAP-positive osteoclasts in the 
tibial metaphysis were indistinguishable from those of wild type mice, but BMM 
differentiation into osteoclasts was impaired in vitro, evident in reduced induction of 
cellular TRAP activity in response to RANKL or TNF-α. These observations suggest 
that Siglec-15 mediates cellular signals through interaction with DAP12 in osteoclasts, 
positively regulating cell differentiation and/or function. Although another 
DAP12-associated receptor, TREM-2, is considered the principal partner of DAP12 in 
osteoclasts, its deficiency in mice reportedly caused accelerated osteoclastogenesis in 
vitro without osteopetrosis in vivo, in contrast to DAP12 deficiency [54]. Taken together, 
my results suggest that the Siglec-15/DAP12 complex mediates the signals required for 
proper osteoclastogenesis more dominantly than the TREM-2/DAP12 complex in mice. 
Furthermore, the differences between in vivo and in vitro osteoclast formation may be 
accounted for by speculating that the Siglec15
−/−
 osteoclasts is capable to differentiate in 
vivo via signaling pathways mediated by other ITAM-bearing adaptors, such as FcRγ; it 
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was suggested that ITAM-bearing adaptors can functionally compensate for each other 
[18, 19]. Recently, Ishida-Kitagawa et al. demonstrated the importance of 
Siglec-15/DAP12-mediated signaling in functional osteoclast formation using chimeras 
of these proteins in vitro [55]. Their results support the relevance of this signaling 
pathway to in vivo osteoclastogenesis. 
  In this study, I generated Siglec15
−/−
 mice, which developed mild osteopetrosis 
resulting from impaired bone resorption. My findings suggest that Siglec-15 functions 
in the regulation of osteoclast differentiation and/or function in vivo.  
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General Discussion 
To identify novel genes involved in osteoclastogenesis, I searched genes whose 
expression was specifically up- or down-regulated in giant cell tumor of bone (GCT). 
Screening by using a human gene expression database identified sialic acid-binding 
immunoglobulin-like lectin 15 (Siglec-15) as one of the genes markedly overexpressed 
in GCT. The mRNA expression level of Siglec-15 increased in association with 
osteoclast differentiation induced by the receptor activator of nuclear factor κB ligand 
(RANKL) in both mouse and human culture systems. Furthermore, treatment of mouse 
and human osteoclast precursors with polyclonal antibody against Siglec-15 markedly 
inhibited their maturation. These results suggest that Siglec-15 induced by RANKL 
through the receptor activator of nuclear factor κB (RANK) is critically involved in 
osteoclastogenesis (Fig. 10). Following completion of the current study, 
Ishida-Kitagawa et al. also reported the importance of Siglec-15 in mouse 
osteoclastogenesis regulation [55]. They identified Siglec-15 as a gene induced by the 
nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1 (NFATc1), a 
key transcription factor for osteoclastogenesis. They also confirmed the inhibitory effect 
of anti-Siglec-15 polyclonal antibody on the osteoclast differentiation and function in a 
mouse bone marrow-derived monocyte/macrophage (BMM) culture system. In addition, 
when Siglec-15 expression was knocked down in mouse BMM by infection with 
retroviral vectors encoding short hairpin RNA specific for Siglec-15, fewer 
multinucleated cells developed even in the presence of RANKL, and those 
multinucleated cells were morphologically contracted with disordered actin-ring 
formation [55]. These changes were accompanied by significantly reduced bone 
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resorption. Most of their results were consistent with those of my current study, and 
support the concept that Siglec-15 plays a critical role in functional osteoclast 
formation. 
The Siglec-15-deficient mice (Siglec15
−/−
) showed increased trabecular bone mass in 
lumbar vertebrae and metaphyseal regions of the femur and tibia, causing mild 
osteopetrosis. Of note, there were no changes in major organs and tissues other than 
skeletal tissues according to the pathological examinations at 18 weeks of age. These 
results suggest that Siglec-15 plays a role specifically in osteoclast physiology. Kameda 
et al. independently generated Siglec-15-deficient mice and reported similar phenotype 
characteristics to those of the current study [56]. Their Siglec15
−/−
 mice were fertile, 
showed no significant abnormalities in appearance, and grew normally until at least 
12 months of age. Increase in the trabecular bone was apparent at the proximal tibia and 
L5 vertebra as determined by micro-CT measurement. The authors also analyzed 
histologic sections of proximal tibia from 9-week old Siglec15
−/−
 mice and found that 
the multinucleated osteoclasts at the secondary spongiosa were small and did not spread 
on the bone surface, implying that Siglec-15 deficiency leads to defective osteoclast 
development. Their results indicate the physiological role of Siglec-15 in osteoclast 
differentiation and function, and strongly support the validity of the results in my 
current study. 
The present study contributes three important elements to our understanding of 
Siglec-15 as a potential therapeutic target for the treatment of metabolic bone diseases. 
First, dysfunction of Siglec-15 led to a defect in bone resorption and the consequent 
increase in bone mass in vivo. Second, anti-Siglec-15 antibody inhibited human 
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osteoclast formation in vitro, providing the concept that antibody medication might be 
effective in clinical use. Finally, a phenotype restricted to skeletal tissues in 
Siglec-15-deficient mice suggests that therapies suppressing Siglec-15 function may 
have fewer adverse effects on other organs or tissues. Recently, Stuible et al. developed 
a monoclonal antibody suppressive to Siglec-15, and reported the effect of the antibody 
on bone mass in young (4-week old) normal mice [57]. Treatment with anti-Siglec-15 
antibody (intraperitoneally injected at 10 mg/kg, twice a week for 4 weeks) led to an 
increase in bone mineral density at the femur, tibia and lumbar spine. In another report, 
Siglec15
−/−
 mice were ovariectomized and examined for estrogen deficiency-induced 
bone loss [58]. The Siglec15
−/−
 mice showed resistance to bone loss compared to 
wild-type mice, suggesting that Siglec-15 is involved in estrogen deficiency-induced 
bone loss. These studies in combination support the notion that anti-Siglec-15 antibody 
is a potential therapeutic agent for postmenopausal osteoporosis. However, a direct in 
vivo study using a pathological animal model needs to be conducted to confirm the 
efficacy of anti-Siglec-15 antibody. In addition to postmenopausal osteoporosis, any 
other bone diseases related to increased osteoclast activity can be considered as target 
indications for anti-Siglec-15 antibody therapy. For example, the most recent study 
demonstrated that Siglec-15-deficient mice showed resistance to periarticular bone loss 
compared to wild-type mice under a condition of antigen-induced arthritis [59], 
suggesting that Siglec-15 blockage may be effective for reducing periarticular bone loss 
in rheumatoid arthritis. 
  Clarifying the signal transduction pathways is a key to understand the physiological 
role of Siglec-15 in the osteoclast regulation. The question can be divided into two 
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parts—what activates Siglec-15 (input signal), and how does Siglec-15 mediate the 
signal intracellularly (output signal). Regarding the input signal, it was reported that 
Siglec-15 preferentially recognizes Neu5Acα2-6GalNAcα-structures, and an arginine 
residue (R143) in the V-set domain is responsible for the binding [29]. Kameda et al. 
constructed a point mutant of Siglec-15 (R143A), in which glycan-binding ability is lost, 
and transfected to Siglec15
−/−
 BMM [56]. Unlike wild-type Siglec-15, the R143A 
mutant was unable to ameliorate the impaired multinuclear osteoclast formation in 
Siglec15
−/−
 cells. Their results suggest that the ligand binding is needed for Siglec-15 to 
stimulate development of functional osteoclasts (Fig. 10). Although the intrinsic ligand 
for Siglec-15 has yet to be identified, we can assume that the putative ligand is 
expressed on osteoclast-lineage cells themselves based on the following two 
experimental facts. First, clonal RAW264.7 cells without any stromal cells or 
osteoblasts could differentiate into mature osteoclasts in the presence of RANKL, and 
anti-Siglec-15 antibody inhibited that differentiation. Second, a previous study showed 
that sialidase treatment of mouse BMM inhibited RANKL-induced formation of 
multinucleated osteoclasts [40], suggesting that desialylation inactivated the putative 
Siglec-15 ligand expressed on the cell surface. Regarding intracellular signal 
transduction, it has been demonstrated that Siglec-15 cooperates with DAP12 in the 
osteoclast regulation [55-57]. DAP12 was reportedly detected in protein complexes 
precipitated with anti-Siglec-15 antibody, and likewise, anti-DAP12 antibody 
precipitated Siglec-15 protein in RAW264.7 cells which differentiated into osteoclasts 
[57]. Further, in mouse BMM in which Siglec-15 expression was knocked down, 
introducing a mutant of Siglec-15 lacking the DAP12-interacting transmembrane lysine 
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residue did not ameliorate the defect in osteoclast formation in contrast to wild-type 
protein [55]. In light of the known role and mechanism of action of DAP12 in osteoclast 
regulation [18, 20], it is assumed that Siglec-15 regulates osteoclast development in 
concert with RANK/RANKL signaling (Fig. 10). DAP12 reportedly regulates osteoclast 
differentiation by modulating RANKL/RANK-mediated calcium signaling, which leads 
to the induction of NFATc1 [18]. However, it was reported that the difference in 
RANKL-induced calcium oscillations between wild-type and Siglec15
−/−
 BMM was 
slight, suggesting that Siglec-15 is not crucial for calcium signaling during osteoclast 
development [56]. DAP12 triggers the activation of Syk, a nonreceptor tyrosine kinase, 
and subsequent multiple signaling pathways which modulate the differentiation and 
cytoskeletal organization of osteoclasts [18, 60-62]. Further studies are required to 
elucidate the responsive downstream signaling pathways of the Siglec-15/DAP12 
complex, which would lead to better understanding of the role of Siglec-15 in the 
biology of osteoclasts. Exploring the intrinsic ligand for Siglec-15 has a profound 
significance for that purpose.  
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Fig. 10. Model of the functional role of Siglec-15 in osteoclast formation. Siglec-15 
induced by RANKL/RANK signaling promotes osteoclast maturation by cooperating 
with RANKL/RANK signaling cascades. Binding of Siglec-15 to the putative ligand is 
supposed to be essential for its activation.  
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